Pyridoxamine Petition Paints Better Option As Dietary Ingredient Than IND
This article was originally published in The Rose Sheet
Executive Summary
ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.
You may also be interested in...
FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA
FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.
FDA Dismisses List Of “Grandfathered” Ingredients In Pyridoxamine Decision
Companies determining whether a substance is a new dietary ingredient cannot rely on industry-developed lists of "grandfathered" ingredients believed to be marketed prior to the Dietary Supplement Health and Education Act, FDA says in response to a citizen petition
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.